Data Sheet (Cat.No.T63253)

TargetMol

AVG-233

Chemical Properties



CAS No. : 2151937-80-1

Formula: C26H22ClN5O3

Molecular Weight: 487.94

Storage: Keep away from direct sunlight,Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	AVG-233 is an orally available RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that blocks respiratory syncytial virus and SARS-CoV-2 replication.AVG-233 is used in the study of respiratory syncytial virus infections.
Targets(IC50)	DNA/RNA Synthesis,RSV
In vitro	AVG-233 (20 μM) exhibits nanomolar activity against both laboratory-adapted RSV strains and clinical RSV isolates[1].
In vivo	In female Balb/cJ mice with recRSV-mKate xenograft, AVG-233 (50 and 100 mg/kg; oral gavage; once) reduced lung viral load by 0.89 log10 TCID50 (median tissue culture infectious dose)/mL[2].

Solubility Information

Solubility	DMSO: 30 mg/mL (61.48 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0494 mL	10.2472 mL	20.4943 mL
5 mM	0.4099 mL	2.0494 mL	4.0989 mL
10 mM	0.2049 mL	1.0247 mL	2.0494 mL
50 mM	0.041 mL	0.2049 mL	0.4099 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cox RM, et al. Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. J Biol Chem. 2018 Oct 26;293(43):16761-16777.
Sourimant J, et al. Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase. Sci Adv. 2022 Jun 24;8(25):eabo2236.